Clinical Trial Update: 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating psilocybin for tobacco use disorder is currently recruiting at Johns Hopkins University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tobacco Use Disorder

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Johns Hopkins University | Conditions: Tobacco Use Disorder | Phase 2 | Status: RECRUITING